KEGG   DRUG: Tremelimumab
Entry
D06657                      Drug                                   
Name
Tremelimumab (USAN/INN);
Tremelimumab (genetical recombination) (JAN);
Tremelimumab-actl;
CP 675206;
Imjudo (TN)
Product
IMJUDO (AstraZeneca Pharmaceuticals LP)
Formula
C6500H9974N1726O2026S52
Exact mass
146289.5973
Mol weight
146380.4722
Sequence
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCRASQSIN SYLDWYQQKP GKAPKLLIYA ASSLQSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YYSTPFTFGP GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Heavy chain)
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV IWYDGSNKYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDP RGATLYYYYY GMDVWGQGTT
VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
VLQSSGLYSL SSVVTVPSSN FGTQTYTCNV DHKPSNTKVD KTVERKCCVE CPPCPAPPVA
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF
NSTFRVVSVL TVVHQDWLNG KEYKCKVSNK GLPAPIEKTI SKTKGQPREP QVYTLPPSRE
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL YSKLTVDKSR
WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
(Disulfide bridge: L23-L88, L134-L194, L214-H139, H22-H96, H152-H208, H265-H325, H371-H429, H227-H'227, H228-H'228, H231-H'231, H234-H'234)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Remark
Therapeutic category: 4291
ATC code: L01FX20
Product: D06657<JP/US>
Efficacy
Antineoplastic, Immune checkpoint inhibitor, Anti-CTLA4 antibody
  Disease
Hepatocellular carcinoma [DS:H00048]
Non-small cell lung cancer [DS:H00014]
  Type
Monoclonal antibody
Comment
Treatment of melanoma
Target
CTLA4 (CD152) [HSA:1493] [KO:K06538]
  Pathway
hsa04514  Cell adhesion molecules
hsa04660  T cell receptor signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX20 Tremelimumab
      D06657  Tremelimumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Tremelimumab
    D06657  Tremelimumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D06657  Tremelimumab (USAN/INN); Tremelimumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D06657  Tremelimumab
Drug classes [BR:br08332]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D06657  Tremelimumab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    CTLA4 (CD152)
     D06657  Tremelimumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D06657
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D06657
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D06657
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D06657
Other DBs
CAS: 745013-59-6
PubChem: 47208308
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system